Literature DB >> 8451612

31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia.

J W Pettegrew1, M S Keshavan, N J Minshew.   

Abstract

A number of studies have demonstrated alterations in the structure and function of the frontolimbic system in some schizophrenic patients. Recent in vivo phosphorus-31 nuclear magnetic resonance studies of the dorsal prefrontal cortex in neuroleptic-naive, first-episode schizophrenic patients and matched controls have shown evidence of alterations in membrane phospholipid and energy metabolism. The membrane alterations observed in the schizophrenic patients are compatible with either premature aging or altered timing and exaggeration of regressive events occurring during normal brain development. These molecular changes may precede onset of clinical symptoms and brain structural changes in schizophrenia and suggest fresh approaches to the pathogenesis and treatment of this illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8451612     DOI: 10.1093/schbul/19.1.35

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  12 in total

1.  Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia.

Authors:  J Brunner; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

2.  Readdressing synaptic pruning theory for schizophrenia: Combination of brain imaging and cell biology.

Authors:  Akiko Hayashi-Takagi; Peter B Barker; Akira Sawa
Journal:  Commun Integr Biol       Date:  2011-03

3.  Metabolic spectroscopy of inflammation in a bleomycin-induced lung injury model using hyperpolarized 1-(13) C pyruvate.

Authors:  Hoora Shaghaghi; Stephen Kadlecek; Charuhas Deshpande; Sarmad Siddiqui; Daniel Martinez; Mehrdad Pourfathi; Hooman Hamedani; Masaru Ishii; Harrilla Profka; Rahim Rizi
Journal:  NMR Biomed       Date:  2014-05-28       Impact factor: 4.044

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia.

Authors:  María D Rubio; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Biol Psychiatry       Date:  2012-03-27       Impact factor: 13.382

7.  Phospholipid biosynthetic enzymes in human brain.

Authors:  B M Ross; A Moszczynska; J K Blusztajn; A Sherwin; A Lozano; S J Kish
Journal:  Lipids       Date:  1997-04       Impact factor: 1.880

8.  Deficit in prepulse inhibition in mice caused by dietary n-3 fatty acid deficiency.

Authors:  Irina Fedorova; Anita R Alvheim; Nahed Hussein; Norman Salem
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

9.  Telomerase levels in schizophrenia: a preliminary study.

Authors:  Barbara Porton; Lynn E Delisi; Hilary C Bertisch; Fei Ji; Derek Gordon; Ping Li; Melissa M Benedict; William M Greenberg; Hung-Teh Kao
Journal:  Schizophr Res       Date:  2008-10-01       Impact factor: 4.939

10.  Multiple forms of the enzyme glycerophosphodiesterase are present in human brain.

Authors:  B M Ross; A L Sherwin; S J Kish
Journal:  Lipids       Date:  1995-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.